Health Boards
Following on from the introduction of Simponi (golimumab) by NICE in April 2011 for England. Scotland has now followed suit, But its use is restricted to patients in whom treatment with at least two other disease-modifying antirheumatic drugs (DMARDs) or NSAIDs has failed to alleviate symptoms. And doses must be restricted to 50mg.
The Scottish Medicines Consortium ruled that the drug can be used alone or in combination with methotrexate. Evidence reviewed by the watchdog found golimumab was cost effective at this dose. A study showed it outperformed placebo at reducing symptoms. Side-effects were similar to placebo and included nasopharyngitis and URTI.
Source: scottishmedicines.org.uk
More on Simponi here: https://psoriasisclub.org/showthread.php...169#pid169
The Scottish Medicines Consortium ruled that the drug can be used alone or in combination with methotrexate. Evidence reviewed by the watchdog found golimumab was cost effective at this dose. A study showed it outperformed placebo at reducing symptoms. Side-effects were similar to placebo and included nasopharyngitis and URTI.
Source: scottishmedicines.org.uk
More on Simponi here: https://psoriasisclub.org/showthread.php...169#pid169